Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
Medicenna Therapeutics Corp (TSE:MDNA)
TSX:MDNA
reports
Medicenna Therapeutics Corp (MDNA) Stock Price & Analysis
117 Followers
MDNA Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$0.54 - C$2.38
Previous CloseC$0.82
Volume33.50K
Average Volume (3M)18.98K
Market Cap
C$45.06M
Enterprise ValueC$8.91M
Total Cash (Recent Filing)C$36.15M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)-5.1
Beta0.46
Next Earnings
Jun 28, 2023EPS Estimate
-C$0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding69,637,469
10 Day Avg. Volume16,884
30 Day Avg. Volume18,982
Standard Deviation0.32
R-Squared0.00559
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)1.51
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Medicenna Therapeutics Corp News
MDNA FAQ
What was Medicenna Therapeutics Corp’s price range in the past 12 months?
Medicenna Therapeutics Corp lowest stock price was C$0.54 and its highest was C$2.38 in the past 12 months.
What is Medicenna Therapeutics Corp’s market cap?
Currently, no data Available
When is Medicenna Therapeutics Corp’s upcoming earnings report date?
Medicenna Therapeutics Corp’s upcoming earnings report date is Jun 28, 2023 which is in 27 days.
How were Medicenna Therapeutics Corp’s earnings last quarter?
Medicenna Therapeutics Corp released its earnings results on Feb 07, 2023. The company reported -C$0.02 earnings per share for the quarter, beating the consensus estimate of -C$0.043 by C$0.023.
Is Medicenna Therapeutics Corp overvalued?
According to Wall Street analysts Medicenna Therapeutics Corp’s price is currently Overvalued.
Does Medicenna Therapeutics Corp pay dividends?
Medicenna Therapeutics Corp does not currently pay dividends.
What is Medicenna Therapeutics Corp’s EPS estimate?
Medicenna Therapeutics Corp’s EPS estimate is -C$0.08.
How many shares outstanding does Medicenna Therapeutics Corp have?
Medicenna Therapeutics Corp has 54,954,610 shares outstanding.
What happened to Medicenna Therapeutics Corp’s price movement after its last earnings report?
Medicenna Therapeutics Corp reported an EPS of -C$0.02 in its last earnings report, beating expectations of -C$0.043. Following the earnings report the stock price went down -0.99%.
Which hedge fund is a major shareholder of Medicenna Therapeutics Corp?
Currently, no hedge funds are holding shares in TSE:MDNA
---
Medicenna Therapeutics Corp Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-37.28%
12-Months-Change
Fundamentals
Return on Equity
-32.99%
Trailing 12-Months
Asset Growth
46.22%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Medicenna Therapeutics Corp
Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines (IL4-ECs) that specifically target the Interleukin-4 Receptor (IL4R) which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The IL4-ECs have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.
---
Microbix Biosystms
―
Covalon Technologies
―
Resverlogix
―
Helix BioPharma
―
Sirona Biochem
―
---